back-office Open An Account
partner-with-us Partner with Us
Corporate Actions
Zim Laboratories gets CDSCO nod for Naproxen'Esomeprazole combination capsule

03-Dec-25   15:30 Hrs IST
The formulation has been developed using the company's proprietary drug delivery technologies, combining naproxen delayed-release minitablets and esomeprazole pellets in a single hard gelatin capsule. Zim said the platform offers a differentiated, patient-friendly delivery system and forms part of its New Innovative Product (NIP) pipeline.

The FDC is indicated for adults for the symptomatic treatment of osteoarthritis, rheumatoid arthritis, and ankylosing spondylitis, and for reducing the risk of NSAID-associated gastric and duodenal ulcers.

Zim Laboratories stated that the approval strengthens its presence in the pain-management and gastro-protective segments. The company has already signed a commercial supply agreement with an Indian pharmaceutical firm and is working toward launching the product in India in FY 2026'27 (FY27). Zim added that the approval aligns with its strategy of developing innovative, differentiated generics using advanced formulation technologies.

ZIM Laboratories is a research-driven pharmaceutical company that develops, manufactures, and supplies differentiated generic products in oral solid dosage forms across key therapeutic segments.

The company's consolidated net profit dropped 117.6% to Rs 0.42 crore as revenue fell 3.7% to Rs 88.71 crore in the quarter ended September 2025 as compared with the previous quarter ended September 2024.

The scrip rose 0.45% to Rs 71.15 on the BSE.

Powered by Capital Market - Live News

Attention Investors: Stock Brokers can accept securities as margin from clients only by way of pledge in the depository system w.e.f. September 1, 2020. || Update your mobile number & email Id with your stock broker/depository participant and receive OTP directly from depository on your email id and/or mobile number to create pledge. || Pay 20% upfront margin of the transaction value to trade in cash market segment. || Investors may please refer to the Exchange's Frequently Asked Questions (FAQs) issued vide circular reference NSE/INSP/45191 dated July 31, 2020 and NSE/INSP/45534 dated August 31, 2020 and other guidelines issued from time to time in this regard. || Check your Securities /MF/ Bonds in the consolidated account statement issued by NSDL/CDSL every month.|| KYC is one time exercise while dealing in securities markets - once KYC is done through a SEBI registered intermediary (broker, DP, Mutual Fund etc.), you need not undergo the same process again when you approach another intermediary.|| No need to issue cheques by investors while subscribing to IPO. Just write the bank account number and sign in the application form to authorise your bank to make payment in case of allotment. No worries for refund as the money remains in investor's account.